Additional fibrate treatment in UDCA-refractory PBC patients

Published on Sep 1, 2019in Liver International5.542
· DOI :10.1111/liv.14165
Sungwon Chung (SNU: Seoul National University), Jeong-Hoon Lee24
Estimated H-index: 24
(SNU: Seoul National University)
+ 11 AuthorsJung-Hwan Yoon44
Estimated H-index: 44
(SNU: Seoul National University)
  • References (47)
  • Citations (0)
📖 Papers frequently viewed together
11 Authors (Hidero Ogino, ..., Nobu Hattori)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Christophe Corpechot (University of Paris)H-Index: 8
#2Olivier Chazouillères (University of Paris)H-Index: 51
Last. Alexandra RousseauH-Index: 8
view all 4 authors...
3 CitationsSource
#1Keith D. Lindor (ASU: Arizona State University)H-Index: 96
#2Christopher L. Bowlus (University of California, Berkeley)H-Index: 41
Last. Marlyn J. Mayo (UTSW: University of Texas Southwestern Medical Center)H-Index: 24
view all 5 authors...
29 CitationsSource
#1Christophe Corpechot (University of Paris)H-Index: 8
#2Olivier Chazouillères (University of Paris)H-Index: 51
Last. Raoul Poupon (University of Paris)H-Index: 18
view all 33 authors...
Abstract Background Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome proliferator–activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with this condition. Methods In this 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 100 patients who had had an inadequate response to...
46 CitationsSource
#1Sook Hyang Jeong (Seoul National University Bundang Hospital)H-Index: 32
3 CitationsSource
#1Julie K. Heimbach (Mayo Clinic)H-Index: 45
#2Laura KulikH-Index: 48
Last. Jorge A. Marrero (UTSW: University of Texas Southwestern Medical Center)H-Index: 51
view all 9 authors...
Author(s): Heimbach, JK; Kulik, LM; Finn, RS; Sirlin, CB; Abecassis, MM; Roberts, LR; Zhu, AX; Murad, MH; Marrero, JA
463 CitationsSource
#1Anna ReigH-Index: 4
#2Pilar SeséH-Index: 1
Last. Albert ParésH-Index: 58
view all 3 authors...
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response
31 CitationsSource
#1David E. J. Jones (University of Newcastle)H-Index: 67
#2Pol BoudesH-Index: 4
Last. Gideon M. Hirschfield (University of Birmingham)H-Index: 51
view all 36 authors...
Summary Background Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome proliferator-activated receptor-delta (PPAR-δ), which is implicated in bile acid homoeostasis. This first-in-class study evaluated the anti-cholestatic effects and safety of seladelpar in patients with an inadequate response to ursodeoxycholic acid. Methods The study was a 12-week, double-blind,...
31 CitationsSource
#2Ulrich BeuersH-Index: 59
Last. Christoph SchrammH-Index: 32
view all 7 authors...
Summary Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goal...
192 CitationsSource
#1Frederik Nevens (Katholieke Universiteit Leuven)H-Index: 63
#2Pietro Andreone (UNIBO: University of Bologna)H-Index: 42
Last. David Shapiro (Intercept Pharmaceuticals)H-Index: 12
view all 32 authors...
BackgroundPrimary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease. MethodsIn this 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to urso...
279 CitationsSource
#1Marco Carbone (University of Cambridge)H-Index: 15
#2Stephen J. Sharp (University of Cambridge)H-Index: 72
Last. George F. Mells (University of Cambridge)H-Index: 19
view all 23 authors...
The biochemical response to ursodeoxycholic acid (UDCA)—so-called “treatment response”—strongly predicts long-term outcome in primary biliary cholangitis (PBC). Several long-term prognostic models based solely on the treatment response have been developed that are widely used to risk stratify PBC patients and guide their management. However, they do not take other prognostic variables into account, such as the stage of the liver disease. We sought to improve existing long-term prognostic models ...
107 CitationsSource
Cited By0
Abstract Cholestasis is a result of obstruction of the biliary tracts. It is a common cause of liver pathology after exposure to toxic xenobiotics and during numerous other liver diseases. Accumulation of bile acids in the liver is thought to be a major driver of liver injury during cholestasis and can lead to eventual liver fibrosis and cirrhosis. As such, current therapy in the field of chronic liver diseases with prominent cholestasis relies heavily on increasing choleresis to limit accumulat...